

## Special Issue

# The Genetic Basis and Molecular Mechanisms of Neurodegeneration

### Message from the Guest Editor

Neurodegenerative disorders include heterogeneous conditions such as Alzheimer's disease; frontotemporal, Lewy body, and other dementias; Parkinson's disease; amyotrophic lateral sclerosis; Huntington's disease; and prion disorders. These disorders pose an important public health threat given their increasing prevalence due to population aging worldwide. This awareness has encouraged efforts to decipher the genetic and molecular mechanisms underlying these disorders with the aim of developing rational therapeutic approaches. Despite their phenotypic diversity, neurodegenerative disorders frequently overlap on clinical grounds and share common pathophysiological mechanisms, such as protein misfolding, defective protein degradation, mitochondrial dysfunction, impaired axonal transport, DNA repeat expansions, DNA damage, excitotoxicity, oxidative stress, and aberrant programmed cell death. The aim of this Special Issue is to include studies that showcase both common and divergent aspects of neurodegenerative disorders, including their genetic and molecular basis, thus advancing knowledge in the field.

### Guest Editor

Dr. Ioannis V. Zaganas

Neurogenetics Laboratory Medical School, University of Crete, 71003 Heraklion, Greece

### Deadline for manuscript submissions

closed (30 June 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/191877](https://mdpi.com/si/191877)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).